New deals will cut Medicare costs for expensive drugs
Aug 15, 2024
The Biden administration said Thursday that it has signed deals with drug companies that will lower the prices on 10 of the most popular and expensive drugs used by American seniors.
Prevalence of homebound 22 percent in national Medicare Advantage plan
Aug 12, 2024
Homebound status linked to increased odds of ED visit, inpatient admission, skilled nursing-facility admission, mortality
Disparities in post-acute stroke care depend on insurance status
Jul 17, 2024
Uninsured patients had the lowest odds of facility versus home discharge and home healthcare discharge versus home without home healthcare.
2011 to 2020 saw increase in annual prescription meds expenditures
Apr 15, 2024
Metabolic agents were the most costly category; antidiabetic agents were the mostly costly therapeutic area.
New federal rule means hospitals need written consent for pelvic, prostate exams
Apr 01, 2024
The HHS also issued a new set of guidelines clarifying a longstanding requirement that hospitals must obtain written informed consent as a condition for being reimbursed by Medicare and Medicaid.
Medicare to cover Wegovy when patients also have heart disease
Mar 22, 2024
Medicare will now cover the popular weight-loss drug Wegovy if patients using it also have heart disease, US officials announced Thursday.
Biogen is dropping controversial Alzheimer’s drug Aduhelm
Jan 31, 2024
Biogen said it will shift its focus to a newer Alzheimer’s drug, Leqembi, which it markets in a partnership with Japan-based Eisai. Leqembi received FDA approval last year.
Racial and ethnic disparities seen in use of hospice
Dec 18, 2023
Older age was associated with lower odds of short length of stay in those dually eligible for Medicare and Medicaid.
Major drug companies agree to price negotiations with US government
Oct 03, 2023
Ten drugs have been chosen for price negotiations by the Centers for Medicare & Medicaid Services.
Heart, diabetes, cancer drugs on list for Medicare price negotiations, White House says
Aug 29, 2023
Enrollees in the Medicare prescription drug program paid a total of $3.4 billion in out-of-pocket costs in 2022 for the 10 initial drugs chosen for price negotiations.